Welcome to LookChem.com Sign In|Join Free

CAS

  • or

55791-66-7

Post Buying Request

55791-66-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

55791-66-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 55791-66-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,5,7,9 and 1 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 55791-66:
(7*5)+(6*5)+(5*7)+(4*9)+(3*1)+(2*6)+(1*6)=157
157 % 10 = 7
So 55791-66-7 is a valid CAS Registry Number.

55791-66-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name ethyl-4-(5-acetyl-2-hydroxy-3-methoxyphenyl)-2-butenoate

1.2 Other means of identification

Product number -
Other names ethyl-4-(n-octadecylamino)benzoate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:55791-66-7 SDS

55791-66-7Downstream Products

55791-66-7Relevant articles and documents

Ortho -Substituted lipidated Brartemicin derivative shows promising Mincle-mediated adjuvant activity

Foster, Amy J.,Kodar, Kristel,Stocker, Bridget L.,Timmer, Mattie S. M.

supporting information, p. 1095 - 1103 (2020/02/22)

The macrophage inducible C-type lectin (Mincle) is a pathogen recognition receptor (PRR) that is a promising target for the development of Th1-polarising vaccine adjuvants. We recently reported on the synthesis and evaluation of lipidated Brartemicin analogues that showed Mincle agonist activity, with our lead agonist exhibiting potent Th1 adjuvant activity that was greater than that of trehalose dibehenate (TDB). Herein, we report on the efficient synthesis and subsequent biological evaluation of additional lipidated Brartemicin analogues that were designed to determine the structural requirements for optimal Mincle signalling. While all the Brartemicin analogues retained their ability to signal through Mincle and induce a functional response, the o-substituted and m,m-disubstituted derivatives (5a and 5d, respectively) induced a potent inflammatory response when using cells of both murine and human origin, with this response being the greatest observed thus far. As the inflammatory response elicited by 5a was slightly better than that induced by 5d, our findings point to o-substituted Brartemicin analogues as the preferred scaffold for further adjuvant development.

Potential antiatherosclerotic agents. 2. (Aralkylamino)- and (alkylamino)benzoic acid analogues of cetaben

Albright,DeVries,Largis,Miner,Reich,Schaffer,Shepherd,Upeslacis

, p. 1378 - 1393 (2007/10/02)

The syntheses of a series of (aralkylamino)- and (alkylamino)benzoic acids, as well as the corresponding esters and sodium salts, are described. The compounds were evaluated in vivo in rats for serum sterol and triglyceride lowering activity and in vitro

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 55791-66-7